Suda Pharmaceuticals - Half-year update
SUDA continues to make progress with anagrelide. In an animal model, SUDA was able to show that an oral spray formulation had 43% higher bioavailability over a capsule form while only showing a 28% increase in exposure of the cardiostimulatory metabolite. This provides evidence that this formulation may allow for a lower dose of anagrelide, maintaining efficacy, but with reduced cardiotoxicity, a significant issue with the capsule formulation. In February, the company announced that it has contracted with MedPharm to perform additional formulation work to stabilise and optimise the oral spray formulation.Suda Pharmaceuticals is engaged in the pharmaceutical development of drug delivery technology; and medical devices and consumables distribution. The drug delivery operation includes the ArTiMist™ project and the oro-mucosal spray drug delivery technology. Co.'s segments include: Suda, which is the pharmaceutical development segment and performs research and development to create new human pharmaceutical products by combining proven drugs with delivery technologies; Westcoast Surgical and Medical Supplies, which is the sales and logistics operation for medical devices and consumables; and Malaria Research Company, which is the pharmaceutical development segment for the treatment of malaria.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.